Oral Cancer Prevalence in Virginia

Purpose. Oral and pharyngeal cancer affects 30,000 Americans a year and kills one fourth of those diagnosed. The primary risk factors for oral cancer are past or present cigarette and tobacco usage, and alcohol consumption in conjunction with tobacco use. Even though the prevalence of oral cancer is relatively low in the younger age groups, this group is most likely to benefit from intervention programs designed to change risky behavior such as smoking, and to prevent oral cancer in the later years. The goal of the study was to identify high-risk target areas for an oral cancer prevention program in Virginia. Methods and Materials. The specific objectives were to analyze the 1986 to 2001 Oral Biopsy Database from the Virginia Commonwealth University School of Dentistry for diagnosed cases of oral cancer. To test the hypothesis that Hampton Roads, Virginia would be a high-risk target area, diagnoses were correlated with the 11 zip-code regions in Virginia to identify specific geographical areas with high numbers of oral cancer cases. The oral cancer data set consisted of 4,712 cases. Frequencies and cross-tabulations were calculated for all the variables using Statistical Package for Social Scientists software (SPSS Inc., version 10.1, Chicago, IL). Results. Results indicated that the Hampton Roads region had the second highest number of squamous cell carcinomas, with 231 total cases. The Richmond area had 435cases, almost twice as many. Conclusions. Therefore, Hampton Roads and Richmond are high-risk target areas that would benefit from an aggressive oral cancer prevention and intervention program in its public schools

Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial.

BackgroundThe AspireAssist is the first Food and Drug Administration-approved endoluminal device indicated for treatment of class II and III obesity.ObjectivesWe earlier reported 1-year results of the PATHWAY study. Here, we report 4-year outcomes.SettingUnited States-based, 10-center, randomized controlled trial involving 171 participants with the treatment arm receiving Aspiration Therapy (AT) plus Lifestyle Therapy and the control arm receiving Lifestyle Therapy (2:1 randomization).MethodsAT participants were permitted to continue in the study for an additional year up to a maximum of 5 years providing they maintained at least 10% total weight loss (TWL) from baseline at each year end. For AT participants who continued the study, 5 medical monitoring visits were provided at weeks 60, 68, 76, 90, and 104 and thereafter once every 13 weeks up to week 260. Exclusion criteria were a history of eating disorder or evidence of eating disorder on a validated questionnaire. Follow-up weight, quality of life, and co-morbidities were compared with the baseline levels. In addition, rates of serious adverse event, persistent fistula, withdrawal, and A-tube replacement were reported. All analyses were performed using a per-protocol analysis.ResultsOf the 82 AT participants who completed 1 year, 58 continued to this phase of the trial. Mean baseline body mass index of these 58 patients was 41.6 ± 4.5 kg/m2. At the end of first year (at the beginning of the follow-up study), these 58 patients had a body mass index of 34.1 ± 5.4 kg/m2 and had achieved an 18.3 ± 8.0% TWL. On a per protocol basis, patients experienced 14.2%, 15.3%, 16.6%, and 18.7% TWL at 1, 2, 3, and 4 years, respectively (P < .01 for all). Forty of 58 patients (69%) achieved at least 10% TWL at 4 years or at time of study withdrawal. Improvements in quality of life scores and select cardiometabolic parameters were also maintained through 4 years. There were 2 serious adverse events reported in the second through fourth years, both of which resolved with removal or replacement of the A tube. Two persistent fistulas required surgical repair, representing approximately 2% of all tube removals. There were no clinically significant metabolic or electrolytes disorders observed, nor any evidence for development of any eating disorders.ConclusionsThe results of this midterm study have shown that AT is a safe, effective, and durable weight loss alternative for people with class II and III obesity and who are willing to commit to using the therapy and adhere to adjustments in eating behavior

On the possible sources of gravitational wave bursts detectable today

We discuss the possibility that galactic gravitational wave sources might give burst signals at a rate of several events per year, detectable by state-of-the-art detectors. We are stimulated by the results of the data collected by the EXPLORER and NAUTILUS bar detectors in the 2001 run, which suggest an excess of coincidences between the two detectors, when the resonant bars are orthogonal to the galactic plane. Signals due to the coalescence of galactic compact binaries fulfill the energy requirements but are problematic for lack of known candidates with the necessary merging rate. We examine the limits imposed by galactic dynamics on the mass loss of the Galaxy due to GW emission, and we use them to put constraints also on the GW radiation from exotic objects, like binaries made of primordial black holes. We discuss the possibility that the events are due to GW bursts coming repeatedly from a single or a few compact sources. We examine different possible realizations of this idea, such as accreting neutron stars, strange quark stars, and the highly magnetized neutron stars (``magnetars'') introduced to explain Soft Gamma Repeaters. Various possibilities are excluded or appear very unlikely, while others at present cannot be excluded.Comment: 24 pages, 20 figure

Optimizing Retrieval of Biospecimens Using the Curated Cancer Clinical Outcomes Database (C3OD)

A grant from the One-University Open Access Fund at the University of Kansas was used to defray the author's publication fees in this Open Access journal. The Open Access Fund, administered by librarians from the KU, KU Law, and KUMC libraries, is made possible by contributions from the offices of KU Provost, KU Vice Chancellor for Research & Graduate Studies, and KUMC Vice Chancellor for Research. For more information about the Open Access Fund, please see http://library.kumc.edu/authors-fund.xml.To fully support their role in translational and personalized medicine, biorepositories and biobanks must continue to advance the annotation of their biospecimens with robust clinical and laboratory data. Translational research and personalized medicine require well-documented and up-to-date information, but the infrastructure used to support biorepositories and biobanks can easily be out of sync with the host institution. To assist researchers and provide them with accurate pathological, epidemiological, and bio-molecular data, the Biospecimen Repository Core Facility (BRCF) at the University of Kansas Medical Center (KUMC) merges data from medical records, the tumor registry, and pathology reports using the Curated Cancer Clinical Outcomes Database (C3OD). In this report, we describe the utilization of C3OD to optimally retrieve and dispense biospecimen samples using these 3 data sources and demonstrate how C3OD greatly increases the efficiency of obtaining biospecimen samples for the researchers.National Cancer Institute (NCI) Cancer Center Support Grant P30 CA168524Biostatistics and Informatics Shared Resource (BISR)Biospecimen Shared Resource (BSR